15 alternatives ranked by AI visibility score. Category: Precision Psychiatry (Treatment-Resistant Depression).
Nasdaq-listed (ANRO). Raised $120M PIPE (2026) to fund ALTO-207 Phase 2b. FDA Fast Track for ALTO-101. Biomarker-stratified psychiatry matching patients to drugs using brain biology. 4 data readouts t...
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clini
Eikon Therapeutics is a drug discovery company that went public on Nasdaq in February 2026 (ticker: EIKN) with a $381 million IPO, armed with a proprietary RESOLFT super-resolution
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (
Stipple Bio is a precision oncology company that emerged from stealth in April 2026 with a $100 million oversubscribed Series A. The round was co-led by RA Capital Management, Andr
Vima Therapeutics is developing VIM0423, the only oral drug in clinical development for isolated dystonia — a movement disorder characterized by involuntary, sustained muscle contr
Mirador Therapeutics is a precision immunology company with a genetics-first platform (Mirador360) that uses human genetic data to identify the most biologically validated targets
Earendil Labs is a full-stack AI biologics company that uses a proprietary AI platform to design protein therapeutics at scale. The company secured $787 million in financing in Mar